More on JNJ
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $253.98 |
|
|||
| Open | $255.78 | ||||
| 52 Wk High | $126.07 | ||||
| 52 Wk Low | $94.28 | ||||
| Day High | $263.10 | ||||
| Day Low | $254.00 | ||||
| P/E | 54.69 | ||||
| EPS | $4.81 | ||||
| Volume | 8,000,739 | ||||
- Increasing unusual put volume: XLI EQT ARKG ROST WEN KOS BKLN UUP DB DJ JNJ LOW FVRR
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- DePuy Synthes names Christina Zamarro as CFO, effective July 2026
- J&J presents new IMAAVY data for myasthenia gravis at EAN 2026
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
- Johnson & Johnson (JNJ) PT Raised to $270 at Guggenheim
- Form 11-K JOHNSON & JOHNSON For: Dec 31
- Form 11-K JOHNSON & JOHNSON For: Dec 31
- Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says
- Johnson & Johnson invests $1 billion in Jacksonville vision manufacturing
Entities mentioned with JNJ
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
